fashion -WSS

fashion

author：knowledge 2025-10-02 00:27:58 - browse：2

Mouse embryo in bottle. -- coverage from STAT — A mouse embryo model created entirely from stem cells. Scientists have since used similar systems to build models of human embryos. Jacob Hanna —Weizmann Institute

Earlier this month, a British journalist broke the news that researchers had taken a major step toward growing stem cells into structures that resemble human embryos.

Details about the experiments, and any sort of outside analysis of their quality or significance, were scarce, since the academic paper summarizing the work was still under peer review. But as the news spread around the globe, other scientists who had more quietly been working in the same area quickly posted preprints of their own progress.

Almost overnight, it seemed, the world was awash in different ways to coax stem cells into something that looked like the earliest days of a human life. The pushback was immediate, prompting accusations of overblown claims as well as outcry about ethical considerations and legal guardrails lagging behind the pace of scientific progress. Meanwhile, former Trump adviser Steve Bannon’s podcast, which studies have found to be a top spreader of misinformation, denounced synthetic babies as “the next abomination.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Abbott's new heart device gets FDA advisory panel nod

focus

WSS

Mirador, a new biotech startup, launches with $400 million

Testing GLP

ACIP vaccine advisory panel sees its vacancies filled

Medical devices makers are asking for forgiveness, not permission

Congress might make insulin pumps more accessible to the blind

Surgeons perform first xenotransplant using CRISPR'd pig kidney

focus

fashion

knowledge

Alkermes shareholders re

Juul documents reveal insider tactics on political lobbying

Psychedelics group wrestles with new pharma identity

CRISPR technology availability, affordability needs to be expanded

Trump demands the U.S. pay no more for drugs than other countries … again

Biotech investment managers search for lucrative opportunities

Peter Hotez and the public health issue of online harassment

Why Eli Lilly’s earnings didn’t quite live up to the hype

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Amylyx, Aurinia, and IQVIA

hotspot

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Bernie Sanders gets little from pharma CEOs on drug prices

Medicare Advantage insurers pressure Biden for bigger payments

Report cites 'urgent' need to recruit more diverse clinical trial participants

Ebola vaccine can save some who are already sick, per new study

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

focus

knowledge

focus